Account
Articles
08.09.2025
Innovative Payment Models: Outcomes‑Based, Annui...

In 2010, the world’s most expensive therapy was Soliris (eculizumab), costing around USD 409,500 p...

Read more
Articles
08.09.2025
ATMP pricing landscape: why traditional models bre...

A €3 million invoice for a single infusion can dazzle as easily as it alarms. Gene therapies such ...

Read more
Articles
10.12.2024
A 2024 update: Is NRDL inclusion in China really t...

The National Healthcare Security Administration (NHSA) of China completed its annual review of the N...

Read more
Insider Insights
23.07.2024
Saudi Arabia’s rise: from emerging market to...

The Saudi Food & Drug Authority (SFDA) released guidelines for Economic Evaluation Studies to assess...

Read more
News
01.06.2022
PMA Insights: Week 22

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
27.05.2022
New coalition to improve access to cancer drugs in

According to the UICC, “priority will be given to medicines currently on the WHO Essential Medicin...

Read more
Articles
25.05.2022
Is Saudi Arabia the indicator for change in the Mi...

Introduction For some manufacturers, launching in the Middle East and North Africa (MENA) is fraught...

Read more
Articles
17.05.2022
Is NRDL inclusion in China really the golden ticke...

Introduction As the most populous country in the world with 1.4 billion inhabitants, China has the p...

Read more
Articles
11.05.2022
How are countries in South-East Asia establishing ...

Introduction Health Technology Assessment (HTA) implementation has been historically slow in Asia co...

Read more
Articles
03.05.2022
What are the top 5 considerations to be aware of b...

Introduction: Brazil is a market of 210 million people Brazil is the largest country in South Americ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.